Investigation of Coagulation Parameters in Hereditary Haemorrhagic Telangiectasia

This study has been completed.
Sponsor:
Collaborator:
Hammersmith Hospitals NHS Trust
Information provided by:
Imperial College London
ClinicalTrials.gov Identifier:
NCT00230659
First received: September 29, 2005
Last updated: NA
Last verified: September 2005
History: No changes posted
  Purpose

The inherited disease hereditary haemorrhagic telangiectasia (HHT) causes bleeding from dilated fragile vessels, particularly in the nose and gut. However, many HHT patients develop deep venous thromboses and/or pulmonary embolism, necessitating treatments with anticoagulants that further impair control of their haemorrhagic state. Our initial observations using general coagulation tests suggest that the blood of HHT patients is intrinsically hypercoagulable.

We hypothesize that the genetically-determined abnormality in the blood vessels of HHT patients leads to alteration in the concentrations or activity of one or several of the proteins which affect blood clotting leading to a hypercoagulable state.

We propose to study levels and activity of blood coagulation factors in people with hereditary haemorrhagic telangiectasia and in normal volunteers. This should define the significance and basis for our initial observations, and will have significant implications for the clinical management of HHT patients.


Condition Phase
Telangiectasia, Hereditary Hemorrhagic
Phase 4

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Investigation of Coagulation Parameters in Hereditary Haemorrhagic

Resource links provided by NLM:


Further study details as provided by Imperial College London:

Estimated Enrollment: 100
Study Start Date: August 2004
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Patients with HHT and normal controls

Exclusion Criteria:

  • Previous thrombosis, recent ill health
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00230659

Locations
United Kingdom
Imperial College Hammersmith Campus
London, United Kingdom, W12 0NN
Sponsors and Collaborators
Imperial College London
Hammersmith Hospitals NHS Trust
Investigators
Principal Investigator: Claire Shovlin Imperial College London
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00230659     History of Changes
Other Study ID Numbers: IC/CLS6
Study First Received: September 29, 2005
Last Updated: September 29, 2005
Health Authority: United Kingdom: Research Ethics Committee

Additional relevant MeSH terms:
Telangiectasis
Telangiectasia, Hereditary Hemorrhagic
Vascular Diseases
Cardiovascular Diseases
Hemostatic Disorders
Hemorrhagic Disorders
Hematologic Diseases
Vascular Malformations
Cardiovascular Abnormalities
Congenital Abnormalities

ClinicalTrials.gov processed this record on October 19, 2014